Figure 2.
RFS following HCT in patients with MDS or AML randomized to receive maintenance azacitidine vs supportive care.

RFS following HCT in patients with MDS or AML randomized to receive maintenance azacitidine vs supportive care.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal